• Imagenomix

  Participated · Seed · May 2026

  Imagenomix has developed a patent-protected AI platform that identifies genetic alterations of cancer directly from standard histopathology images and maps the spatial distribution of those mutations without DNA sequencing. The company is a New York City–based spinout of NYU Langone Health and is led by CEO Travis Wold. Imagenomix plans to focus initially on lung, brain, and breast cancers. It intends to initiate a clinical trial in breast cancer and to commercially launch a V2 lung cancer classifier later this year in collaboration with Proscia. The firm also supports an alliance with Alterome Therapeutics, which is applying the technology in Phase I therapeutic trials. Financially, Imagenomix recently raised $3.2 million in seed funding to support these development, clinical, and commercial activities.

• RetiSpec

  Participated · Series A · Jul 2024

  RetiSpec develops AI solutions applied to non-invasive retinal images to identify neurodegenerative disease markers and provide real-time results at the point of care. Its first clinically validated AI is intended to predict amyloid burden to aid evaluation for Alzheimer’s disease. RetiSpec’s solutions are currently available for Research Use Only. The company aims to enable widespread early and accurate detection of neurodegenerative disease through a routine eye exam. Leadership is headed by co-founder and CEO Eliav Shaked. The company is based in Toronto, Canada and has raised $17M USD to date.

• Pathway

  Participated · Seed · Nov 2023

  Pathway is an AI-driven medical knowledge platform that distills practice guidance from millions of evidence-based sources into concise summaries to help clinicians stay current and deliver high-quality care. The platform has a fast-growing community of over 350,000 registered healthcare professionals. From its inception in 2020, Pathway has combined physician-vetted data with physician-grade AI to power clinical decision support and search. The company is making its clinical decision support tool open access and has launched Pathway AI in limited beta, its most advanced assistant and search tool. Pathway’s clinical AI assistant scored higher than 97% of human test takers on the USMLE and surpassed the accuracy of MedPaLM 2 on that benchmark. The company plans to use new funding to accelerate technology rollout and expand its reach to clinicians globally. Pathway operates an AI-powered medical knowledge platform that uses natural language processing and machine learning to provide evidence-based answers to clinical questions. Its mobile app is available to healthcare professionals on the Apple App Store and will soon be on Google Play; the company has also released an enterprise version of its clinical decision support technology. Pathway delivers interactive “pathways” that guide clinicians step-by-step through diagnostic approaches and treatments, aggregating more than 1,000 guidelines and over 45,000 graded recommendations across 33 medical specialties. The product is used by clinicians in more than 180 countries and reports a net promoter score of 69. Pathway says it typically reduces decision time from minutes to seconds and aims to help hospitals disseminate their own guidelines more efficiently. The recent $1.3M raise will be used to scale operations and expand software functionality to support additional use cases.

• Doctorkoi

  Led · Seed · Jun 2022

  Doctor Koi is a Dhaka-based digital healthcare startup. The company announced a US$500,000 seed investment from Verge HealthTech Fund. The round was also joined by undisclosed industry and local investors. Verge HealthTech Fund is an early-stage healthcare tech venture capital fund focusing on the Asia‑Pacific, the Middle East, and North Africa. The article does not provide details about Doctor Koi’s product roadmap, future plans, operating metrics, revenue, or user numbers.

• Shen.AI @ MX Labs

  Participated · Seed · Feb 2022

  MX Labs develops Shen.AI, an AI-powered monitoring system that uses remote photoplethysmography (rPPG) and computer vision to measure heart performance, blood pressure, and other vital indicators. The technology aims to enable early detection and monitoring of lifestyle-related disorders such as hypertension. The startup primarily serves telemedicine clients across more than 20 countries. Founders Remigiusz Kościelny and Przemysław Jaworski lead the company’s product and technical efforts. The company plans to use new capital to advance Shen.AI and expand its market presence. The financing details reported did not disclose the amount. MX Labs develops Shen.AI, a computer-vision and deep-learning diagnostic engine that uses a smartphone or computer camera to measure heart rate, heart rate variability and blood pressure from a one-minute facial scan. The technology is currently embedded in Heart Monitor, a mobile app available on the Apple App Store and Google Play (coming soon on CheckBP.com), which has been downloaded by over 80,000 people. With new funding, the company plans to expand Shen.AI's cardiovascular and mental-health capabilities and add functionality such as emotional-state detection and behavioral markers. MX Labs says it will invest in high-quality data acquisition, external collaborations with scientific institutions, and medical certification to position the product for telemedicine use. The founders have stated a goal of offering a medically certified diagnostic solution accessible through consumer devices and to deliver the expanded features to first customers later this year. The company is based in Estonia and frames its product as an affordable remote monitoring tool for prevention, self-care and telemedicine augmentation. MX Labs develops Shen.AI, a computer-vision and vital-signs platform that powers two smartphone apps—Heart Monitor and Beauty—to deliver contactless measurements of pulse, blood pressure, HRV, breathing rate, skin and eye assessments using only a camera. The apps are designed to be free to download with premium subscription features; the company says it will offer premium tiers though pricing details were not disclosed. MX Labs is pursuing AAMI-level blood-pressure accuracy, plans clinical trials, and aims for SaMD and CE certification once accuracy targets are met. The company provides an SDK for integration with mobile, desktop and embedded hardware and plans to add sensor and external data streams (e.g., Google Fit, Apple Health) for improved accuracy and telemedicine use cases. MX Labs is working with medical institutions including Antoni Jurasz University Hospital No. 1 in Bydgoszcz and partners in Africa and Southeast Asia to collect several thousand labeled recordings for model training; research participants are offered a free three-month app subscription. The team numbered eight at the time of reporting and the startup plans to grow to about 14 employees by year end.

No current team members are available.